Business
DiaMedica Therapeutics Provides a Business Update and Announces First Quarter 2022 Financial Results
Conference Call and Webcast May 5 at 8:00 am Eastern Time / 7:00 am Central Time Continuing to Expand Clinical Study Sites in Pivotal Phase 2/3 ReMEDy2 Acute
About this update from Diamedica Therapeutics Inc.
[{"type":"text","content":"\nConference Call and Webcast May 5 at 8:00 am Eastern Time / 7:00 am Central Time\n\n\nContinuing to Expand Clinical Study Sites in Pivotal Phase 2/3 ReMEDy2 Acute Ischemic Stroke Trial\n\n\n\nCash Runway Into 2024\n\n\n MINNEAPOLIS--(BUSINESS WIRE)--\nDiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for neurological disorders and kidney diseases, today provided a business update and released financial results for the quarter ended March 31, 2022. DiaMedica will host a conference call on Thursday, May 5, 2022, at 8:00AM Eastern Time / 7:00AM Central Time, to discuss its business update and first quarter financial results.\n\nClinical Developments\n\nDM199 for the Treatment of Acute Ischemic Stroke\n\nDiaMedica reported that it has increased the number of activated clinical trial sites to 9, more than doubling the number of active sites reported in March 2022 and is currently on track with its site activation goals for its ReMEDy2 trial, which is an adaptive design, randomized, double-blind, placebo-controlled trial studying the use of the Company’s product candidate, DM199, to treat acute ischemic stroke (AIS). DiaMedica believes that it has experienced slower than expected site activations and enrollment in the ReMEDy2 trial due primarily to staffing shortages and overall resourcing at study sites due to the COVID-19 pandemic and challenges of the study sites managing logistics and compliance for patients discharged from the hospital to an intermediate care facility. The Company is putting resources and processes in place to address both of these issues and expects continued improvement in site activations and patient enrollment over the course of 2022, subject to new pandemic related challenges which may arise for study sites.\n\nDM199 for the Treatment of Chronic Kidney Disease\n\nAs previously reported, patient enrollment is completed in DiaMedica’s Phase 2 REDUX trial, which is a multi-center, open-label, investigation to assess the safety and efficacy of multiple doses of DM199, administered over 90 days, in participants with chronic kidney disease (CKD) (Stage 2 or 3).\n\nIn total, 79 patients were enrolled and initiated treatment, including 21 African American patients in Cohort 1, 25 patients with IgAN in Cohort 2 and 33 patients with Type 2 d...